NVNONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
enVVeno Medical Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.69+0.22 (+2.95%)
Close on Oct 19, 2026
- Market cap
- $5.16M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 4, 2026 | Before market open | – | – | – |
| Q4 FY2018 Ended Dec 31, 2018 | Mar 13, 2019 | Before market open | – | – | – |
Press releases
Announcements enVVeno Medical filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Results of operations · Other events · EX-99.1 to Form 8-K
Receives Unfavorable Appeal Decision from the FDA for the VenoValve
Regulation FD disclosure · EX-99.1 to Form 8-K
Receives Not-Approvable Letter from the FDA for the VenoValve®
Regulation FD disclosure · EX-99.1 to Form 8-K
be Presented Today at the 46 th Annual Charing Cross Symposium
Regulation FD disclosure · EX-99.1 to Form 8-K
Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve ® Pivotal Trial to
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50 th
Regulation FD disclosure · EX-99.1 to Form 8-K